Forest Lab, Merz Pharma announced that they have filed a second lawsuit in the U.S. District Court for the District of Delaware against additional companies for infringement of US5061703 (the '703 patent) which covers a method for the prevention or treatment of cerebral ischemia comprising the step of administering, to a patient in need thereof, an effective amount of an adamantane derivative like Memantine hydrochloride. The defendants named in the lawsuit include Dr. Reddy's Laboratories Limited, Genpharm Inc., Interpharm Inc., Mylan Pharmaceuticals Inc., Ranbaxy Laboratories Limited, Sun India Pharmaceutical Industries Limited, and related companies and subsidiaries thereof. The '703 patent expires in April 2010. Forest has applied for patent term extension which, if granted, would extend the '703 patent until September 2013.
As previously reported, Forest and Merz had received notification from several companies that they had filed Abbreviated New Drug Applications (ANDA) with Paragraph IV certifications to obtain approval to market generic versions of Namenda and commenced an action in patent infringement in the U.S. District Court in Delaware against such filers.
As previously reported, Forest and Merz had received notification from several companies that they had filed Abbreviated New Drug Applications (ANDA) with Paragraph IV certifications to obtain approval to market generic versions of Namenda and commenced an action in patent infringement in the U.S. District Court in Delaware against such filers.
